Zobrazeno 1 - 10
of 451
pro vyhledávání: '"Kim A Papp"'
Autor:
Kurt de Vlam, Alan Kivitz, Andrew J K Ostor, Zailong Wang, Ahmed M Soliman, Ann Eldred, Kim A Papp, Byron Padilla
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objectives Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR) and/or ≥1 conventional synthe
Externí odkaz:
https://doaj.org/article/838882eaf5b84a6c88601c84524195e0
Autor:
Kenneth B. Gordon, Andrew Blauvelt, Hervé Bachelez, Laura C. Coates, Filip E. Van den Bosch, Blair Kaplan, Willem Koetse, Doug G. Ashley, Ralph Lippe, Ranjeeta Sinvhal, Kim A. Papp
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2523-2538 (2024)
Abstract Introduction Risankizumab has demonstrated a favourable safety profile in patients with psoriatic disease (moderate-to-severe psoriasis [PsO] and psoriatic arthritis [PsA]). We evaluated the long-term safety of risankizumab in psoriatic dise
Externí odkaz:
https://doaj.org/article/83030d6abf4e47649d18fb5fdcb77867
Autor:
Mark G. Kirchhof, Vimal H. Prajapati, Melinda Gooderham, Chih-ho Hong, Charles W. Lynde, Catherine Maari, Irina Turchin, Kim A. Papp
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2653-2668 (2024)
Abstract Oral Janus kinase inhibitors (JAKi), a class of advanced targeted systemic therapy, have demonstrated efficacy and safety in the treatment of moderate-to-severe atopic dermatitis (AD). Like other small molecules, oral JAKi have the potential
Externí odkaz:
https://doaj.org/article/2df4c74225a647e78bc9952cf007f5a2
Autor:
April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2577-2589 (2024)
Abstract Introduction Treating plaque psoriasis (PsO) with guselkumab (GUS) promotes skin clearance and is associated with improvements in health-related quality of life (HRQoL), anxiety, and depression. It is unclear whether improvements in patient-
Externí odkaz:
https://doaj.org/article/2e1fbdbdc341498ebebba1f697824c23
Autor:
April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2235-2248 (2024)
Abstract Introduction Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravac
Externí odkaz:
https://doaj.org/article/eb30f9d6f1ac4e2b804fb11e94392dce
Autor:
Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp
Publikováno v:
JID Innovations, Vol 4, Iss 5, Pp 100287- (2024)
Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses. Selective blockade of IL-23p19 with guselkum
Externí odkaz:
https://doaj.org/article/b95df6bc33d542458a2fcbb40566670b
Autor:
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A. Papp
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data
Externí odkaz:
https://doaj.org/article/109029d531134ab5b27492e558a2ff92
Autor:
Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-16 (2024)
Abstract Background We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondy
Externí odkaz:
https://doaj.org/article/1bc182a808cb4b8a907eae62f5ff0a85
Autor:
Kim A. Papp, Barbara Melosky, Sandeep Sehdev, Sebastien J. Hotte, Jennifer R. Beecker, Mark G. Kirchhof, Irina Turchin, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Jo Lambert, Charles W. Lynde, Vimal H. Prajapati, Ronald B. Vender
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 867-889 (2023)
Abstract Background Patients with treated solid tumours (TSTs) are a highly heterogeneous population at an increased risk for malignancy compared with the general population. When treating psoriasis in patients with a history of TSTs, clinicians are
Externí odkaz:
https://doaj.org/article/062de13938e141a89117a95d3fedf09a
Autor:
Kim A. Papp, Jennifer Beecker, Curtis Cooper, Mark G. Kirchhof, Anton L. Pozniak, Juergen K. Rockstroh, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Charles W. Lynde, Catherine Maari, Yves Poulin, Ronald B. Vender, Sharon L. Walmsley
Publikováno v:
Dermatology and Therapy, Vol 12, Iss 5, Pp 1073-1089 (2022)
Abstract Background People living with human immunodeficiency virus (PLHIV) have a similar prevalence of psoriasis as the general population, though incidence and severity correlate with HIV viral load. Adequately treating HIV early renders the infec
Externí odkaz:
https://doaj.org/article/a8e3ca70c7c04b0ea1cd9216fab2a8e2